GURUFOCUS.COM » STOCK LIST » USA » NYSE » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » ROE %
Switch to:

Bristol-Myers Squibb Co ROE %

: 17.71% (As of Jun. 2022)
View and export this data going back to 1952. Start your Free Trial

ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. Bristol-Myers Squibb Co's annualized net income attributable to common stockholders for the quarter that ended in Jun. 2022 was $5,684 Mil. Bristol-Myers Squibb Co's average Total Stockholders Equity over the quarter that ended in Jun. 2022 was $32,090 Mil. Therefore, Bristol-Myers Squibb Co's annualized ROE % for the quarter that ended in Jun. 2022 was 17.71%.

The historical rank and industry rank for Bristol-Myers Squibb Co's ROE % or its related term are showing as below:

BMY' s ROE % Range Over the Past 10 Years
Min: -20.16   Med: 13.31   Max: 38.18
Current: 19

During the past 13 years, Bristol-Myers Squibb Co's highest ROE % was 38.18%. The lowest was -20.16%. And the median was 13.31%.

BMY's ROE % is ranked better than
86.38% of 1028 companies
in the Drug Manufacturers industry
Industry Median: 3.99 vs BMY: 19.00

Bristol-Myers Squibb Co ROE % Historical Data

The historical data trend for Bristol-Myers Squibb Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.21 38.18 10.48 -20.16 18.96

Bristol-Myers Squibb Co Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.34 16.71 25.94 15.14 17.71

Competitive Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Bristol-Myers Squibb Co ROE % Distribution

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's ROE % distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's ROE % falls into.



Bristol-Myers Squibb Co ROE % Calculation

Bristol-Myers Squibb Co's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income attributable to Common Stockholders (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=6994/( (37822+35946)/ 2 )
=6994/36884
=18.96 %

Bristol-Myers Squibb Co's annualized ROE % for the quarter that ended in Jun. 2022 is calculated as

ROE %=Net Income attributable to Common Stockholders (Q: Jun. 2022 )/( (Total Stockholders Equity (Q: Mar. 2022 )+Total Stockholders Equity (Q: Jun. 2022 ))/ count )
=5684/( (31580+32600)/ 2 )
=5684/32090
=17.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Jun. 2022) net income attributable to common stockholders data. ROE % is displayed in the 30-year financial page.


Bristol-Myers Squibb Co  (NYSE:BMY) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %**(Q: Jun. 2022 )
=Net Income/Total Stockholders Equity
=5684/32090
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(5684 / 47548)*(47548 / 101695.5)*(101695.5 / 32090)
=Net Margin %*Asset Turnover*Equity Multiplier
=11.95 %*0.4676*3.1691
=ROA %*Equity Multiplier
=5.59 %*3.1691
=17.71 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %**(Q: Jun. 2022 )
=Net Income/Total Stockholders Equity
=5684/32090
=(Net Income /Pre-Tax Income) * (Pre-Tax Income/Operating Income) * (Operating Income/Revenue) * (Revenue/Total Assets) * (Total Assets/Total Stockholders Equity)
= (5684 / 7832) * (7832 / 10568) * (10568 / 47548) * (47548 / 101695.5) * (101695.5 / 32090)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7257 * 0.7411 * 22.23 % * 0.4676 * 3.1691
=17.71 %

Note: The net income attributable to common stockholders data used here is four times the quarterly (Jun. 2022) net income attributable to common stockholders data. The Revenue data used here is four times the quarterly (Jun. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Bristol-Myers Squibb Co ROE % Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co Business Description

Bristol-Myers Squibb Co logo
Address
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Executives
Greenlees Sharon officer: SVP & Controller BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Shanahan Karin officer: EVP, Glob. Prod. Dev. & Supply BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Meyers Gregory Scott officer: EVP, Chief Digital & Tech Off. BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Weese Michelle officer: EVP, Corporate Affairs BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Hidalgo Medina Manuel director BRISTOL MYERS SQUIBB 430 E. 29TH STREET, 14TH FLOOR NEW YORK NY 10016
Rice Derica W director 1000 NICOLLET MALL TPS-3155 MINNEAPOLIS MN 55403
Price Paula A director ONE CVS DRIVE WOONSOCKET RI 02895
Mily Elizabeth officer: EVP, Strategy & BD BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVENCE LINE ROAD PRINCETON NJ 08540
Metcalfe Kathryn officer: EVP, Corporate Affairs BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Vessey Rupert officer: Pres., Research & Early Dev. C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Elkins David V officer: EVP, Chief Financial Officer C/O BECTON, DICKINSON AND COMPANY 1 BECTON DRIVE FRANKLIN LAKES NJ 07417
Bonney Michael W director 65 HAYDEN AVE LEXINGTON MA 02421
Yale Phyllis R director
Ahmed Nadim officer: President, Hematology C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Haller Julia A director C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901

Bristol-Myers Squibb Co Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)